Stem Cell Industry Eyes FDA Roundtables by Year-End — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Chuck Meeker, a stem cell entrepreneur, told STAT at the PepMed 2026 conference that he expects "a series of FDA roundtables" on stem cells before the end of the year, though the FDA declined to confirm any such events were imminent
- Peptides and stem cells both fall under regenerative medicine, which markets therapies claimed to trigger the body's natural healing, but compounded peptides have gained FDA traction while commercially available, unapproved stem cell therapies remain a "black sheep" for the agency
- Stem cell industry advocates at PepMed 2026 framed the FDA's peptide engagement as a template to bring their therapies "from the grey market to millions of Americans"
- The American Academy of Peptide Medicine hosted the PepMed 2026 conference in Washington, where Meeker and other regenerative-medicine figures made the case for parallel FDA engagement with stem cells
- Unapproved stem cell therapies have stayed outside mainstream FDA pathways even as compounded peptides moved into the agency's tentative good graces, creating the asymmetry industry advocates now want closed
Why it matters: Stem cell advocates are explicitly modeling their FDA strategy on the peptide playbook, betting the agency's tentative embrace of regenerative medicine opens a path to legitimize unapproved therapies currently sold in a grey market — a shift that would redraw the line between FDA-sanctioned and direct-to-consumer regenerative treatments.
Ask SkimNews
